Natco Pharma Q1 Result: Profit Falls 57% YoY To Rs 207 Crore; Revenue Down 45% YoY

Operating performance also remained under pressure, with earnings before interest, tax, depreciation and amortisation (EBITDA) declining 67.4% YoY to Rs 186 crore from Rs 571 crore.